GlassScriptPhysician profile
Jonathan A Dunn
NPI 1538123732
$2,602.37
in general payments reported to CMS, 2019-2025
29 companies · $732 in 2025
The $732 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $177 · 2021: $27.91 · 2022: $227 · 2023: $230 · 2024: $986 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,948.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $558.49 | 2023-2024 | Veozah |
| Mayne Pharma Commercial LLC | $519.89 | 2022-2025 | |
| Intuitive Surgical, INC. | $144.36 | 2019 | |
| Therapeuticsmd, INC. | $143.12 | 2020 | |
| Applied Medical Resources Corporation | $136.68 | 2022 | |
| Becton, Dickinson and Company | $125.43 | 2023-2025 | Arista Ah Flexitip, Bd Onclarity |
| Biogen, INC. | $125.36 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $104.87 | 2023-2024 | Myfembree |
| Evofem Biosciences, INC. | $97.64 | 2020-2024 | |
| Meditrina | $74.23 | 2024-2025 | |
| Abbvie INC. | $50.35 | 2022-2023 | Oriahnn, Lo Loestrin Fe, Orilissa |
| Pfizer INC. | $50.27 | 2024-2025 | |
| Daiichi Sankyo INC. | $48.46 | 2024 | Injectafer |
| Millicent US INC | $45.26 | 2025 | Femlyv, Intrarosa |
| Coopersurgical, INC. | $40.38 | 2019-2024 | Paragard T 380a |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $39.54 | 2021-2025 | Slynd |
| Hologic Sales and Service, LLC | $35.92 | 2024-2025 | Fetal Fibronectin Enzyme Immunoassay, Acessa Provu System, Novasure |
| Vertex Pharmaceuticals Incorporated | $34.68 | 2025 | |
| Viiv Healthcare Company | $34.22 | 2025 | Apretude |
| Sanofi Pasteur INC. | $32.49 | 2024 | |
| Philips North America LLC | $24.23 | 2025 | Vest Therapy Und |
| Bayer Healthcare Pharmaceuticals INC. | $23.10 | 2023 | |
| Myovant Sciences INC. | $22.76 | 2022 | |
| Amag Pharmaceuticals, INC. | $18.91 | 2019 | |
| Dysis Medical, INC. | $18.26 | 2019 | |
| Ascend Therapeutics US, LLC | $17.60 | 2020 | |
| Minerva Surgical, INC | $12.84 | 2019 | |
| Avion Pharmaceuticals | $11.71 | 2021 | |
| Duchesnay USA Incorporated | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.